6.690USD+1.83%Mkt Cap: 449.11M USDP/E: —Last update: 2026-05-26
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United St…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap449.11M USD
Enterprise Value111.66M USD
Revenue (TTM)—
Gross Profit-56.78M USD
Net Income (TTM)-74.88M USD
Revenue/Share—
Last Price6.690 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.96
PEG—
EV/EBITDA-1.31
EV/Revenue—
P/S—
P/B1.32
EPS (TTM)-1.15
EPS (Forward)-1.33
52W Range
5.8808% of range15.74
52W High15.74 USD
52W Low5.880 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.46%
ROA-20.44%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.06M USD
CapEx (TTM)314.00K USD
FCF Margin—
FCF Yield-8.40%
Net Debt-327.45M USD
Net Debt/EBITDA3.84
Balance Sheet
Debt/Equity0.02
Current Ratio34.33
Quick Ratio33.97
Book Value/Sh5.004 USD
Cash/Share5.002 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)18.90 USD
Target Range8.000 USD – 25.00 USD
# Analysts10
Ownership
Shares Out.66.63M
Float47.97M
Insiders3.86%
Institutions108.02%
Short Interest
Short Ratio8.1d
Short % Float12.10%
Short % Out.11.96%
Shares Short7.97M
Short (prev mo.)6.96M
Technical
SMA 507.300 (-8.4%)
SMA 2008.800 (-24.0%)
Beta3.01
S&P 52W Chg28.31%
Avg Vol (30d)674.62K
Avg Vol (10d)533.25K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—